Uveal Melanoma: Diagnosis, Classification and Management

  • Ronel Veksler
  • Ido Didi FabianEmail author


Uveal melanoma (UM) is the most common primary intraocular malignancy in adults. It arises from melanocytes in the choroid, ciliary body and, less frequently, iris, and affects mainly light-skinned individuals in their sixth decade of life. Diagnosis of UM is often based on clinical examination, including slit lamp biomicroscopy, and ancillary studies, especially ultrasound. Biopsy is rarely required for diagnosis, but performed in selected cases for prognostication. In clinical practice, in addition to anatomical location, UM is routinely classified according to tumor dimensions, with large tumors (>8 mm in height) known to be associated with significantly higher chances for distant metastatic spread and death. Most UM cases are treated conservatively by means of plaque or proton beam radiotherapy, resulting with high tumor control rate, but also compromised vision due to late radiotherapy related complications.


Uvea Melanoma Choroid Nevus Ultrasound Radiotherapy 


  1. 1.
    Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83:1664–78.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Hu D-N, Yu G-P, McCormick SA, Schneider S, Finger PT. Population-based incidence of uveal melanoma in various races and ethnic groups. Am J Ophthalmol. 2005;140:612.e1–8.CrossRefGoogle Scholar
  3. 3.
    Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118:1881–5.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol. 1988;32:239–51.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Virgili G, et al. Incidence of uveal melanoma in Europe. Ophthalmology. 2007;114:2309–2315.e2.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    McLaughlin CC, et al. Incidence of noncutaneous melanomas in the U.S. Cancer. 2005;103:1000–7.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Harbour JW, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330:1410–3.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Shields CL, et al. Association of ocular and oculodermal melanocytosis with the rate of uveal melanoma metastasis: analysis of 7872 consecutive eyes. JAMA Ophthalmol. 2013;131:993–1003.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Gallagher RP, et al. Risk factors for ocular melanoma: Western Canada Melanoma Study. J Natl Cancer Inst. 1985;74:775–8.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Chien JL, Sioufi K, Surakiatchanukul T, Shields JA, Shields CL. Choroidal nevus: a review of prevalence, features, genetics, risks, and outcomes. Curr Opin Ophthalmol. 2017;28:228–37.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Singh AD, Kalyani P, Topham A. Estimating the risk of malignant transformation of a choroidal nevus. Ophthalmology. 2005;112:1784–9.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Shields CL, et al. Choroidal nevus transformation into melanoma. Arch Ophthalmol. 2009;127:981.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Damato EM, Damato BE. Detection and time to treatment of uveal melanoma in the United Kingdom: an evaluation of 2384 patients. Ophthalmology. 2012;119:1582–9.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Finn AP, Materin MA, Mruthyunjaya P. Choroidal tumor biopsy. Retina. 2018;38:S79–87.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Shields CL, et al. American joint committee on cancer classification of uveal melanoma (anatomic stage) predicts prognosis in 7731 patients. Ophthalmology. 2015;122:1180–6.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Shields JA, Shields CL. Management of posterior uveal melanoma: past, present, and future: the 2014 Charles L. Schepens lecture. Ophthalmology. 2015;122:414–28.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Fabian ID, et al. Primary photodynamic therapy with verteporfin for small pigmented posterior pole choroidal melanoma. Eye. 2017;31:519–28.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Accuracy of diagnosis of choroidal melanomas in the Collaborative Ocular Melanoma Study. COMS report no. 1. Arch Ophthalmol. 1990; 108:1268–1273.Google Scholar
  19. 19.
    Khan S. Clinical and pathologic characteristics of biopsy-proven iris melanoma. Arch Ophthalmol. 2012;130:57.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Shields JA, Eagle RC, Ferguson K, Shields CL. Tumors of the nonpigmented epithelium of the ciliary body. Retina. 2015;35:957–65.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Shields JA, Sanborn GE, Augsburger JJ. The differential diagnosis of malignant melanoma of the iris. A clinical study of 200 patients. Ophthalmology. 1983;90:716–20.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Shields JA, Mashayekhi A, Ra S, Shields CL. Pseudomelanomas of the posterior uveal tract: the 2006 Taylor R. Smith Lecture. Retina. 2005;25:767–71.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Bianciotto C, et al. Assessment of anterior segment tumors with ultrasound biomicroscopy versus anterior segment optical coherence tomography in 200 cases. Ophthalmology. 2011;118:1297–302.Google Scholar
  24. 24.
    Shields CL, Kaliki S, Rojanaporn D, Ferenczy SR, Shields JA. Enhanced depth imaging optical coherence tomography of small choroidal melanoma: comparison with choroidal nevus. Arch Ophthalmol. 2012;130:850–6.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Shields CL, et al. Chromosome 3 analysis of uveal melanoma using fine-needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases. Arch Ophthalmol. 2007;125:1017.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Sagoo MS, et al. Plaque radiotherapy for juxtapapillary choroidal melanoma. JAMA Ophthalmol. 2014;132:697.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Margo CE. The collaborative ocular melanoma study: an overview. Cancer Control. 2004;11:304–9.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    McLean IW, Foster WD, Zimmerman LE, Martin DG. Inferred natural history of uveal melanoma. Invest Ophthalmol Vis Sci. 1980;19:760–70.Google Scholar
  29. 29.
    McLean IW, Foster WD, Zimmerman LE, Martin DG. Inferred natural history of uveal melanoma. Invest Ophthalmol Vis Sci. 1980;19:760–70.Google Scholar
  30. 30.
    Shields CL, et al. Iris melanoma outcomes based on the American joint committee on cancer classification (eighth edition) in 432 patients. Ophthalmology. 2018;125:913–23.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Zakka KA, Foos RY, Omphroy CA, Straatsma BR. Malignant melanoma. Analysis of an autopsy population. Ophthalmology. 1980;87:549–56.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Kath R, et al. Prognosis and treatment of disseminated uveal melanoma. Cancer. 1993;72:2219–23.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Zimmerman LE, McLean IW, Foster WD. Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells. Br J Ophthalmol. 1978;62:420–5.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Fabian ID, et al. Secondary enucleations for uveal melanoma: a 7-year retrospective analysis. Am J Ophthalmol. 2015;160:1104–1110.e1.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Stallard HB. Radiotherapy for malignant melanoma of the choroid. Br J Ophthalmol. 1966;50:147–55.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol. 2006;124:1684–93.Google Scholar
  37. 37.
    Gündüz K, Shields CL, Shields JA, Cater J, Brady L. Plaque radiotherapy for management of ciliary body and choroidal melanoma with extraocular extension. Am J Ophthalmol. 2000;130:97–102.CrossRefGoogle Scholar
  38. 38.
    Shields CL, et al. Iris melanoma management with iodine-125 plaque radiotherapy in 144 patients: impact of melanoma-related glaucoma on outcomes. Ophthalmology. 2013;120:55–61.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Sagoo MS, et al. Plaque radiotherapy for juxtapapillary choroidal melanoma overhanging the optic disc in 141 consecutive patients. Arch Ophthalmol. 2008;126:1515–22.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Agraval U, et al. Use of ruthenium-106 brachytherapy for iris melanoma: the Scottish experience. Br J Ophthalmol. 2018;102:74–8.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Fernandes BF, et al. Management of iris melanomas with 125Iodine plaque radiotherapy. Am J Ophthalmol. 2010;149:70–76.e2.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Sagoo MS, et al. Plaque radiotherapy for juxtapapillary choroidal melanoma. Ophthalmology. 2011;118:402–7.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Krema H, et al. Management of ciliary body melanoma with iodine-125 plaque brachytherapy. Can J Ophthalmol. 2009;44:395–400.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Gragoudas ES, et al. Proton beam irradiation. An alternative to enucleation for intraocular melanomas. Ophthalmology. 1980;87:571–81.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Zografos L, et al. Rapport sur le traitement conservateur des mélanomes de l’uvée a la clinique ophtalmologique universitaire de Lausanne∗. Klin Monatsbl Augenheilkd. 1988;192:572–8.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Dendale R, et al. Proton beam radiotherapy for uveal melanoma: results of Curie Institut–Orsay Proton Therapy Center (ICPO). Int J Radiat Oncol. 2006;65:780–7.CrossRefGoogle Scholar
  47. 47.
    Damato B, Kacperek A, Chopra M, Campbell IR, Errington RD. Proton beam radiotherapy of choroidal melanoma: the Liverpool-Clatterbridge experience. Int J Radiat Oncol Biol Phys. 2005;62:1405–11.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Papakostas TD, Lane AM, Morrison M, Gragoudas ES, Kim IK. Long-term outcomes after proton beam irradiation in patients with large choroidal melanomas. JAMA Ophthalmol. 2017;135:1191.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Shah SU, et al. Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma. Ophthalmology. 2014;121:269–75.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Shields JA, Glazer LC, Mieler WF, Shields CL, Gottlieb MS. Comparison of xenon arc and argon laser photocoagulation in the treatment of choroidal melanomas. Am J Ophthalmol. 1990;109:647–55.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Meyer-Schwickerath G, Vogel M. Treatment of malignant melanomas of the choroid by photocoagulation. Trans Ophthalmol Soc U K. 1977;97:416–20.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Oosterhuis JA, Journée-de Korver HG, Kakebeeke-Kemme HM, Bleeker JC. Transpupillary thermotherapy in choroidal melanomas. Arch Ophthalmol. 1995;113:315–21.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Singh AD, Kivelä T, Seregard S, Robertson D, Bena JF. Primary transpupillary thermotherapy of ‘small’; choroidal melanoma: is it safe? Br J Ophthalmol. 2008;92:727–8.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Jmor F, Hussain RN, Damato BE, Heimann H. Photodynamic therapy as initial treatment for small choroidal melanomas. Photodiagn Photodyn Ther. 2017;20:175–81.CrossRefGoogle Scholar
  55. 55.
    Rundle P. Treatment of posterior uveal melanoma with multi-dose photodynamic therapy. Br J Ophthalmol. 2014;98:494–7.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Fabian ID, et al. Primary photodynamic therapy with verteporfin for pigmented posterior pole cT1a choroidal melanoma: a 3-year retrospective analysis. Br J Ophthalmol. 2018;102(12):1705–10. Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  1. 1.Ocular Oncology ServiceGoldschleger Eye Institute, Sheba Medical Center, Tel-Aviv UniversityTel AvivIsrael

Personalised recommendations